Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.
Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tüting T, Belardelli F, Bracci L, La Sorsa V, Ziccheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti R, Spano JP, Pusztai L, Poirier-Colame V, Delaloge S, Penault-Llorca F, Ladoire S, Arnould L, Cyrta J, Dessoliers MC, Eggermont A, Bianchi ME, Pittet M, Engblom C, Pfirschke C, Préville X, Uzè G, Schreiber RD, Chow MT, Smyth MJ, Proietti E, André F, Kroemer G, Zitvogel L. Sistigu A, et al. Among authors: conforti r. Nat Med. 2014 Nov;20(11):1301-9. doi: 10.1038/nm.3708. Epub 2014 Oct 26. Nat Med. 2014. PMID: 25344738 Clinical Trial.
Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands.
Conforti R, Ma Y, Morel Y, Paturel C, Terme M, Viaud S, Ryffel B, Ferrantini M, Uppaluri R, Schreiber R, Combadière C, Chaput N, André F, Kroemer G, Zitvogel L. Conforti R, et al. Cancer Res. 2010 Jan 15;70(2):490-500. doi: 10.1158/0008-5472.CAN-09-1890. Epub 2010 Jan 12. Cancer Res. 2010. PMID: 20068181
How to improve the immunogenicity of chemotherapy and radiotherapy.
Ma Y, Conforti R, Aymeric L, Locher C, Kepp O, Kroemer G, Zitvogel L. Ma Y, et al. Among authors: conforti r. Cancer Metastasis Rev. 2011 Mar;30(1):71-82. doi: 10.1007/s10555-011-9283-2. Cancer Metastasis Rev. 2011. PMID: 21298323 Review.
Desirable cell death during anticancer chemotherapy.
Locher C, Conforti R, Aymeric L, Ma Y, Yamazaki T, Rusakiewicz S, Tesnière A, Ghiringhelli F, Apetoh L, Morel Y, Girard JP, Kroemer G, Zitvogel L. Locher C, et al. Among authors: conforti r. Ann N Y Acad Sci. 2010 Oct;1209:99-108. doi: 10.1111/j.1749-6632.2010.05763.x. Ann N Y Acad Sci. 2010. PMID: 20958322 Review.
TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer.
Salaun B, Zitvogel L, Asselin-Paturel C, Morel Y, Chemin K, Dubois C, Massacrier C, Conforti R, Chenard MP, Sabourin JC, Goubar A, Lebecque S, Pierres M, Rimoldi D, Romero P, Andre F. Salaun B, et al. Among authors: conforti r. Cancer Res. 2011 Mar 1;71(5):1607-14. doi: 10.1158/0008-5472.CAN-10-3490. Epub 2011 Feb 22. Cancer Res. 2011. PMID: 21343393
CXCR4 expression in early breast cancer and risk of distant recurrence.
Andre F, Xia W, Conforti R, Wei Y, Boulet T, Tomasic G, Spielmann M, Zoubir M, Berrada N, Arriagada R, Hortobagyi GN, Hung MC, Pusztai L, Delaloge S, Michiels S, Cristofanilli M. Andre F, et al. Among authors: conforti r. Oncologist. 2009 Dec;14(12):1182-8. doi: 10.1634/theoncologist.2009-0161. Epub 2009 Nov 25. Oncologist. 2009. PMID: 19939894 Free article. Clinical Trial.
Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials.
Conforti R, Boulet T, Tomasic G, Taranchon E, Arriagada R, Spielmann M, Ducourtieux M, Soria JC, Tursz T, Delaloge S, Michiels S, Andre F. Conforti R, et al. Ann Oncol. 2007 Sep;18(9):1477-83. doi: 10.1093/annonc/mdm209. Epub 2007 May 21. Ann Oncol. 2007. PMID: 17515403 Free article. Clinical Trial.
101 results